Drew Burdon

Drew Burdon is a Partner at EQT Life Sciences, an esteemed healthcare investment firm, since March 2022. In addition to this role, Drew holds multiple board positions, including at Phagenesis Ltd, Onera Health, FundamentalVR, Neurent Medical, and LUMA Vision. Prior to joining EQT Life Sciences, Drew served as an Investment Manager at LSP from January 2019 to March 2022. Drew's extensive experience includes leadership roles at Smith & Nephew, where responsibilities spanned corporate development and strategic planning from November 2005 to December 2018, and as a Postdoctoral Researcher at Cancer Research UK from December 2002 to November 2005. Educational qualifications include an MBA from The Open University, a PhD in Cell and Molecular Biology from the University of Leicester, and a BSc in Medical Biochemistry from the University of Leicester.